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Abstract
Background The burden of invasive meningococcal dis-
ease is substantial in older adults in whom the case fatality
rate is high. Travelers to regions with high rates of
meningococcal disease, such as Hajj pilgrims, are at
increased risk of meningococcal infection, and disease
transmission from travelers to their close contacts has been
documented. In younger individuals, meningococcal con-
jugate vaccines offer advantages over polysaccharide vac-
cines in terms of duration of protection and boostability,
and induction of herd immune effects through reductions in
nasopharyngeal carriage of meningococci. To date, few
data are available evaluating meningococcal conjugate
vaccine use in adults [55 years of age.
Objective To evaluate the immunogenicity and safety of
quadrivalent meningococcal serogroups A, C, W-135 and
Y vaccine with all serogroups conjugated to tetanus toxoid
(MenACWY-TT, NimenrixTM, GlaxoSmithKline, Bel-
gium) and a licensed quadrivalent polysaccharide vaccine
(MenPS, MencevaxTM GlaxoSmithKline, Belgium) in
adults [55 years of age.
Methods This was a phase IIIb, open-label, randomized
(3:1), controlled study conducted at one study center in
Lebanon. A total of 400 healthy adults between 56 and
103 years of age without previous MenPS or tetanus toxoid
vaccination within the previous 5 years or meningococcal
conjugate vaccination at any time previously were inclu-
ded. They received a single-dose vaccination with Men-
ACWY-TT or MenPS with blood sampling before and
1 month after vaccination. The main outcome measures
were serum bactericidal activity (rabbit complement
source: rSBA) vaccine response (VR) rate [rSBA titer of
C1:32 in initially seronegative subjects (rSBA titer \1:8);
C4-fold increase in subjects with pre-vaccination rSBA
titers between 1:8 and 1:128, and C2-fold increase in
subjects with pre-vaccination rSBA titers C1:128]. The
percentages of subjects with rSBA titers C1:8 and C1:128
and rSBA geometric mean titers (GMTs) were assessed.
Solicited adverse events were recorded for 4 days follow-
ing vaccination, and all other adverse events, including the
incidence of new onset chronic diseases, were recorded for
31 days after vaccination.
Results One month after a single dose of MenACWY-TT,
the rSBA VR rate in the MenACWY-TT group was 76.6 %
for serogroup A, 80.3 % for serogroup C, 77.5 % for se-
rogroup W-135 and 81.9 % for serogroup Y. VR rates in
the MenPS group were 91.7, 84.8, 87.1 and 89.1 %,
respectively. One month after vaccination, C93.2 % of
subjects in the MenACWY-TT group and C93.9 % in the
MenPS group had rSBA titers C1:128. In each group,
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GMTs increased by C13-fold for each serogroup. rSBA
VR and GMTs tended to be lower in subjects who were
over 65 years compared to 56–65 years of age. Only 6.3 %
of MenACWY-TT recipients had anti-TT C0.1 IU/ml prior
to vaccination, increasing to 28.1 % post-vaccination. The
rSBA GMTs were 1.9- to 4-fold higher in anti-TT
responders. Each local and general solicited symptom was
reported by no more than 3.0 % of subjects in either group.
No serious adverse events were considered vaccine related.
Conclusion In adults 56 years of age and older, Men-
ACWY-TT was immunogenic, with a vaccine response
rate C76 % and with C93 % of subjects achieving rSBA
titers C1:128 against all four serogroups after a single dose.
MenACWY-TT induced low anti-TT concentrations in this
population, which deserves further study.
1 Background
Invasive disease caused by Neisseria meningitidis is typi-
cally characterized by rapid onset with fulminant progres-
sion, resulting in death in around 10 % of individuals
despite appropriate antibiotics and supportive care [1]. The
incidence of invasive meningococcal disease is highest in
infants, with a second peak that occurs during adolescence
[2]. Notwithstanding, a substantial proportion of the dis-
ease burden lies with adults: in the US approximately 43 %
of all invasive meningococcal disease cases were reported
in adults aged 25 years and older (1998–2007 data) [2].
During the same observation period, 14 % of cases
occurred in the age group 65 years and older, with a case
fatality rate of 23.8 %, the highest in any age group [2].
Similar trends are observed in other countries: in Australia
6 % of all meningococcal cases in 2010 were in adults over
65 years of age, and 19 % were in adults 45 years of age
and older [3]. In England and Wales, around 10 % of all
meningococcal cases each year between 1993 and 2004
occurred in adults over 45 years of age [4]. These data
point to a substantial disease burden in older adults, which
is likely to become a greater public health concern as the
global population ages.
Based on differences in the composition of the poly-
saccharide capsule, 12 meningococcal serogroups have
been identified; however, 6 serogroups predominate as
causes of invasive disease (serogroups A, B, C, W-135, X
and Y) [5]. In the Middle East, available information
suggests that serogroups A and W-135 are responsible for
the majority of meningococcal invasive disease in the
region. Serogroups A and W-135 are also responsible for
major epidemics in Africa [1, 5], while serogroup X
emerged more recently as a cause of local outbreaks in
Africa [6–9]. By contrast, serogroups A, W-135 and X are
infrequently identified in many Western countries, where
serogroups B, C and to a lesser degree Y predominate
[2, 5].
Adults are at increased risk of meningococcal infection
when they travel to meningococcal endemic regions [10].
A serogroup W-135 outbreak that occurred during the 2000
Hajj spread intercontinentally from pilgrims to their con-
tacts [11, 12], and more recently, cases of W-135 were
identified in France among travellers who had returned
from West Africa and their contacts [13]. These cases of
intercontinental transmission highlight the relative ease by
which meningococcal strains can be transmitted to immu-
nologically naı¨ve populations through global travel activ-
ity. Meningococcal vaccination against serogroups A, C,
W-135 and Y is now required prior to Hajj attendance for
all pilgrims over 2 years of age [14].
Vaccination is the best strategy to prevent meningo-
coccal disease. Quadrivalent serogroups A, C, W-135 and
Y (ACWY) meningococcal polysaccharide vaccines are
available for use in adults and children from the age of
2 years [15]. However, polysaccharide vaccines do not
stimulate T-cell-dependent immune responses and thus do
not induce long-lasting protection or immune memory, but
may induce immune hyporesponsiveness, particularly for
serogroup C, on repeated administration [16, 17]. By
contrast, meningococcal conjugate vaccines induce T-cell-
mediated immune responses that appear to be long-lived,
with evidence of immune memory upon re-exposure [15].
Long-term protection against invasive meningococcal dis-
ease appears to be dependent on the presence of circulating
antibody rather than on memory responses [18]. Antibody
levels decrease over time after both meningococcal poly-
saccharide and meningococcal conjugate vaccination, and
the duration of protection afforded by meningococcal
conjugate vaccination is not yet known.
Conjugate vaccines also induce herd protection by
decreasing the carriage rate in vaccine recipients, which
was demonstrated in the UK after a mass vaccination
program with conjugate serogroup C vaccines [19]. Herd
protection is important in interrupting the transmission of
meningococci. Meningococcal conjugate vaccines there-
fore have advantages in terms of duration of protection and
boostability in those who require sustained protection. In
adults, meningococcal ACWY (MenACWY) conjugate
vaccines show comparable or improved immunogenicity
versus polysaccharide vaccines [20–22]. However, few
studies have evaluated conjugate vaccine use in adults over
55 years of age [20].
GlaxoSmithKline has developed a MenACWY vaccine
with all serogroups conjugated to tetanus toxoid (Men-
ACWY-TT, NimenrixTM), which is licensed for use in
Europe as a single dose in individuals as of 1 year of age
[23]. MenACWY-TT was immunogenic and well tolerated
in clinical trials conducted in children, adolescents and
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adults up to age 55 years [21, 22, 24–30]. We conducted a
phase IIIb, open-label, randomized, controlled study
designed to evaluate the immunogenicity and safety of
MenACWY-TT as compared to a licensed polysaccharide
vaccine (MencevaxTMACWY, GlaxoSmithKline Vaccines:
MenPS) when administered as one dose to healthy adults
aged 56 years and older.
2 Methods
2.1 Study Design
The study (113807, www.clinicaltrials.gov NCT01235975)
was conducted in a single center in Lebanon between 30
November 2010 and 3 August 2011. Adults were enrolled
and randomized 3:1 into two parallel groups. Subjects in the
MenACWY-TT group received a single dose of Men-
ACWY-TT, while subjects in the MenPS group received a
single dose of licensed MenPS. A randomization list was
generated at GlaxoSmithKline Belgium and was used to
number the vaccines. Treatment allocation at the investigator
site was performed using a central, web-based randomization
system. A blocking scheme ensured that balance between
treatments was maintained. The randomization algorithm used
a minimization procedure accounting for center and age strata.
The enrollment ensured a 2:1 allocation of the population
across two age strata: 56–65 years of age and[65 years of age.
This was an open study because the routes of adminis-
tration of the study vaccine and the control vaccine were
different.
The primary study objective was to evaluate the
immunogenicity of MenACWY-TT as compared to MenPS
in terms of serum bactericidal activity (rabbit complement
source; rSBA) vaccine response (VR) rates 1 month after
vaccination. A VR was defined as an rSBA titer of at least
1:32 in initially seronegative subjects (rSBA titer\1:8), at
least a four-fold increase in subjects with rSBA titers
between 1:8 and 1:128 before vaccination and at least a
two-fold increase in subjects with rSBA titers C1:128
before vaccination.
2.2 Study Subjects
Adults were to be at least 56 years of age at enrollment,
and females were to be of non-child bearing potential.
Subjects were not enrolled if they had received prior vac-
cination with MenPS or tetanus toxoid (TT) within the
previous 5 years or with any meningococcal conjugate
vaccine at any time previously. Subjects were also exclu-
ded if they had previously suffered from meningococcal
disease, if they were immunosuppressed for any reason
including chronic ([14 days) immunosuppressant treatment,
if they had a history of neurological disease, seizures or
Guillain-Barre syndrome, or if they had active pulmonary,
cardiovascular, hepatic or renal disease. Subjects who had
received blood products within 3 months of vaccination or
who had chronic alcohol consumption or drug abuse were
also ineligible to participate.
2.3 Study Vaccines
One 0.5 ml dose of MenACWY-TT contained 5 lg each of
meningococcal serogroup A, C, W-135 and Y polysac-
charide conjugated to a total of approximately 44 lg TT.
One 0.5-ml dose of MenPS contained 50 lg each of
meningococcal serogroups A, C, W-135 and Y polysac-
charide. MenACWY-TT was administered intramuscularly
and MenPS given subcutaneously into the upper arm on the
non-dominant side.
2.4 Immunogenicity Assessment
Blood samples were collected from all subjects before and
1 month after vaccination and were tested for rSBA for
each meningococcal serogroup as previously described
[31]. The cutoff of the rSBA assay was a 1:8 dilution and
was considered indicative of seroprotection [32, 33]. Anti-
TT antibodies were measured at each time point using an
enzyme-linked immunosorbent assay (ELISA) [34], with
an assay cutoff of 0.1 IU/ml.
2.5 Safety and Reactogenicity Assessment
Specific local and general symptoms were recorded on
diary cards for 4 days after vaccination. Symptom intensity
of redness, swelling and fever was graded by millimeter of
reaction and degrees Celsius of fever, respectively, and all
other symptoms were graded by the subject using a pre-
defined scale. Grade 3 redness and swelling were defined as
diameter [50 mm, grade 3 fever as oral temperature
[39.5C, and for other symptoms, grade 3 was defined as
preventing normal activity. All other adverse events
including serious adverse events and new onset of chronic
illness were recorded for 31 days after vaccination.
2.6 Consent Procedures
The study protocol was approved by the institutional review
board (IRB) prior to study start. Written informed consent
was obtained from each subject prior to enrollment.
Enrollment was hampered by the distance between
home communities and the study center in Beirut. In
response, the principal investigator proposed setting up a
mobile unit to perform study visits by study personnel in
local villages, as per protocol. A mobile unit guidance
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explaining the rationale for the mobile unit and the asso-
ciated procedures was issued to the IRB for their infor-
mation and the enrollment via the mobile unit started on
the same day. Later, the IRB clarified that approval of the
mobile unit was required. The IRB approved the mobile
unit pending minor revisions a few days later. One hundred
and two subjects were enrolled through the mobile unit
prior to formal IRB mobile unit approval. All of these
subjects were asked to re-consent. Twenty-nine subjects
didn’t re-consent (no subjects refused to re-consent because
of an adverse event), and therefore these 29 subjects were
eliminated from all statistical analyses.
2.7 Statistical Analyses
As this is the first study to investigate the immunogenicity of
MenACWY-TT in a population of older adults, this
exploratory study was designed as a descriptive analysis.
The primary analysis of immunogenicity was done on the
according-to-protocol (ATP) cohort for immunogenicity,
which included subjects who had complied with all protocol-
defined procedures and who had data available for at least
one immunogenicity endpoint. Percentages of subjects with
rSBA vaccine response and with titers/concentrations above
threshold values, with exact 95 % CIs, were calculated. The
effect of age at vaccination and of meningococcal vaccina-
tion history was investigated in exploratory analyses.
The target enrollment was set at 400 subjects random-
ized 3:1 to the MenACWY-TT group or MenPS group in
order to have 360 evaluable subjects (270 subjects in
MenACWY-TT group and 90 subjects in MenPS group),
assuming a 10 % drop out of subjects throughout the study.
With 270 evaluable subjects in the MenACWY-TT group
and assuming a VR rate of 80 %, the exact 95 % CI around
the estimate would be 74.7; 84.6. With 90 evaluable sub-
jects in the MenPS group, the 95 % CI around the assumed
VR rate of 80 % would be 70.2; 87.7.
Exploratory analyses were used to highlight potential
differences between groups if the asymptotic standardized
95 % CI for the group difference in the percentage of
subjects reaching specified immunological cutoffs did not
contain the value ‘0’ or if the 95 % CI for the geometric
mean titer (GMT) ratio (ANCOVA model using the pre-
vaccination logarithm10 transformation of the titers/
concentrations, the vaccine group, age strata and menin-
gococcal vaccination history as covariates) between groups
did not contain the value ‘1’. Multiple comparisons were
done without adjustment for multiplicity, and there is a risk
that statistically significant differences may have occurred
by chance alone. Thus, any statistically significant differ-
ences between groups should be interpreted cautiously.
Exploratory analyses for statistical differences were per-
formed on the cohort including all subjects; these analyses
were not performed per age strata because of the limited
available sample size per stratum.
The primary analysis of safety was done on the total
vaccinated cohort, comprising all vaccinated subjects with
safety data available.
Statistical analyses were performed using SAS soft-




Four hundred adults whose age ranged between 56 and
103 years were enrolled in the study. Of these, 2 subjects
were not vaccinated, and 29 were excluded from all sta-
tistical analyses (see Sect. 2). Thus, there were 369 subjects
in the total vaccinated cohort, of which 260 (70 %) were
eligible for inclusion in ATP analyses (Fig. 1). More
females (68.3 %) than males (31.7 %) were enrolled. The
two treatment groups were comparable in terms of demo-
graphic characteristics (Table 1).
One subject (an 84-year-old subject in the MenPS
group) withdrew from the study because of a serious
adverse event. This subject suffered a cerebrovascular
accident and died 21 days after vaccination. The event was
considered unrelated to vaccination by the investigator.
3.2 Immunogenicity
After a single dose of MenACWY-TT, the VR rate in the
MenACWY-TT group was 76.6 % for serogroup A,
80.3 % for serogroup C, 77.5 % for serogroup W-135 and
81.9 % for serogroup Y (Table 2). VR rates in the MenPS
group were 91.7, 84.8, 87.1 and 89.1 %, respectively.
One month after vaccination, at least 97.4 % in the
MenACWY-TT group and at least 95.5 % in the MenPS
group had rSBA titers C1:8 (Table 3). The percentage with
rSBA C1:128 was at least 93.2 % in the MenACWY-TT
group and at least 93.9 % in the MenPS group. In each
group, GMTs increased by at least 13-fold for each sero-
group (Table 3).
Exploratory analyses did not detect any statistically
significant differences between groups in terms of the
percentage of subjects who reached the 1:8 and 1:128
thresholds after vaccination. However, these analyses
suggested that the magnitude of the response was statisti-
cally significantly lower in MenACWY-TT recipients than
in MenPS recipients in terms of VR rate for serogroup A
and rSBA GMTs for serogroups A and C. VR rates in
individuals with pre-existing rSBA titers C1:128 tended to
be lower for each serogroup in MenACWY-TT recipients
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(65.7–72.6 %) than in MenPS recipients (75.9–91.3 %),
while the majority of initially seronegative subjects in both
groups demonstrated VRs to each serogroup after vacci-
nation (for serogroup A, 93.3 % in the MenACWY-TT
group and 100 % in the MenPS group; for serogroup C,
96.3 and 90.9 %; for W-135, 88.7 and 86.4 %; and for Y,
100 % in both groups).
3.3 Effect of Age and Previous Meningococcal
Polysaccharide Vaccination on the Immune
Response
VR rates tended to be lower in subjects who were
[65 years of age at the time of vaccination, compared to
younger (56- to 65-year-old) subjects (Table 2). This trend
was more pronounced in MenPS recipients for serogroups
A, C and Y. Possible differences between groups were not
statistically tested as these tests are not powered to do so,
because of the low numbers of subjects in each subgroup.
The percentage of subjects with rSBA titers C1:128 and
the rSBA GMT were within the same range in the
56–65 year and [65 year subgroups, although the small
number of subjects in each group means that conclusions
cannot be drawn (Supplementary table 1).
Approximately one-quarter of subjects had a history of
having received a meningococcal polysaccharide vaccine
more than 5 years previously (Table 1). Prior to vaccina-
tion, the percentage of subjects with rSBA C1:128 was
between 57.5 and 60.7 % for serogroup A, 43.9 and 45.3 %
for serogroup C, 48.4 and 52.1 % for serogroup W-135 and
62.4 and 71.9 % for serogroup Y (Table 3). The percentage
of subjects with pre-vaccination titers C1:128 and rSBA
GMTs for serogroups A and C, but not W-135 or Y, tended
to be higher in subjects with a history of meningococcal
vaccination than in unvaccinated subjects (Supplementary
table 2). In the MenACWY-TT group, the post-vaccination
rSBA GMTs in subjects who had not received a menin-






•Non-compliance with blood 
sampling schedule (58)
•Blood sample not taken or 
quantity not sufficient for any test, 
invalid result (17)
Total vaccinated cohort N=274
MenPS
Total vaccinated cohort N=95
29 eliminated
•Protocol violation (1)
•Study vaccine not administered 
per protocol (1) 
•Non-compliance with blood 
sampling schedule (19)
•Blood sample not taken or 
quantity not sufficient for any 




Enrolled and randomized N=400
17 withdrew: 
•Consent withdrawal (8)
•Moved from study area (2)
•Lost to follow up (7)
7 withdrew: 
•SAE (1 subject died)
•Consent withdrawal (2)
•Moved from study area (1)





29  excluded from all statistical 
analyses*
Study vaccine not administered to 2 
subjects
MenACWY-TT
Fig. 1 Subject flow through the
study. ATP according to
protocol, SAE serious adverse
event. *Twenty-nine subjects
(randomized and vaccinated)
who were enrolled via the
mobile unit prior to approval
and who did not re-consent after
mobile unit approval by the
institutional review board
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subjects who had received a prior meningococcal vacci-
nation, although lower point values for rSBA-W-135 titers
were observed in those previously vaccinated: for sero-
group A, 1,372.0 [95 % CI 1,088.3; 1,729.6] versus 1,726.4
[1,067.5; 2,792.0]; for serogroup C, 2,584.3 [1,836.2;
3,637.2] versus 2,412.1 [1,504.7; 3,866.7]; for serogroup
W-135, 1,791.7 [1,369.7; 2,343.7] versus 756.2 [406.2;
1,407.7]; and for serogroup Y, 2,664.0 [2,107.0; 3,368.3]
versus 2,219.6 [1,324.1; 3,720.6]. In the MenPS group, the
rSBA GMTs were: for serogroup A, 2,640.3 [1,768.5;
3,941.9] versus 3,968.1 [2,248.5; 7,003.0]; for serogroup C,
5,054.1 [2,661.9; 9,595.9] versus 4,712.0 [1,483.6;
14,965.4]; for serogroup W-135, 2,217.4 [1,363.6; 3,606.0]
versus 1,325.9 [334.1; 5,261.7]; and for serogroup Y,
4,370.4 [2,756.7; 6,928.6] versus 3,710.3 [2,042.1;
6,741.0]. Due to the low numbers of subjects in each
subgroup, comparisons between groups are not reliable
(Supplementary table 2).
3.4 Response to Tetanus Toxoid
Few subjects had anti-TT antibodies C0.1 IU/ml prior to
vaccination (12 subjects, 6.3 % in the MenACWY-TT
group and 6 subjects, 9.1 % in the MenPS group). The anti-
TT response after MenACWY-TT vaccination was low
(Table 4).
A post-hoc analysis assessed rSBA GMTs in subjects
according to pre- and post-vaccination anti-TT antibody status
in the MenACWY-TT group. In adults with anti-TT anti-
bodies C0.1 IU/ml prior to vaccine, post-vaccination rSBA
GMTs after MenACWY-TT were as high or higher than those
observed in the MenPS group for serogroups C, W-135 and Y,
but not for serogroup A (rSBA GMT 2,479.8 [95 % CI
1,211.4; 5,076.2] for serogroup A, 7,492.7 [2,069.9; 27,121.6]
for serogroup C, 3,250.5 [521.4; 20,263.8] for serogroup
W-135, and 3,992.0 [1,028.7; 15,491.2] for serogroup Y,
Supplementary table 3). Furthermore, the post-vaccination
Table 1 Summary of demographic characteristics (total vaccinated
cohort)
Characteristic MenACWY-TT N = 274 MenPS N = 95
Age (years)
Mean (SD) 64.1 (7.22) 64.3 (7.39)
Range 56–103 56–86
Age stratum (years) n (%)
56–65 184 (67.2) 63 (66.3)
[65 90 (32.8) 32 (33.7)
Gender n (%)
Female 182 (66.4) 70 (73.7)
Male 92 (33.6) 25 (26.3)
Geographic ancestry n (%)
Arabic/North African 274 (100) 95 (100)
Meningococcal vaccination historya n (%)
Unknown 2 (0.7) 2 (2.1)
0 210 (76.6) 68 (71.6)
1 62 (22.6) 25 (26.3)
2 0 (0.0) 0 (0.0)
N total number of subjects, n/% number/percentage of subjects in a
given category, SD standard deviation
a Number of previous meningococcal polysaccharide vaccinations.
Note that previous meningococcal vaccines were received more than
5 years prior to enrollment
Table 2 Percentage of subjects with a vaccine response 1 month after vaccination: all subjects and by age strata (ATP cohort for
immunogenicity)
Serogroup Group All subjects 56- to 65-year-olds [65-year-olds
N n % [95 % CI] N n % [95 % CI] N n % [95 % CI]
A MenACWY-TT 175 134 76.6* [69.6; 82.6] 119 93 78.2 [69.6; 85.2] 56 41 73.2 [59.7; 84.2]
MenPS 60 55 91.7 [81.6; 97.2] 37 37 100 [90.5; 100] 23 18 78.3 [56.3; 92.5]
C MenACWY-TT 188 151 80.3 [73.9; 85.7] 128 106 82.8 [75.1; 88.9] 60 45 75.0 [62.1; 85.3]
MenPS 66 56 84.8 [73.9; 92.5] 41 38 92.7 [80.1; 98.5] 25 18 72.0 [50.6; 87.9]
W-135 MenACWY-TT 187 145 77.5 [70.9; 83.3] 127 102 80.3 [72.3; 86.8] 60 43 71.7 [58.6; 82.5]
MenPS 62 54 87.1 [76.1; 94.3] 38 33 86.8 [71.9; 95.6] 24 21 87.5 [67.6; 97.3]
Y MenACWY-TT 188 154 81.9 [75.7; 87.1] 128 103 80.5 [72.5; 86.9] 60 51 85.0 [73.4; 92.9]
64 57 89.1 [78.8; 95.5] 39 37 94.9 [82.7; 99.4] 25 20 80.0 [59.3; 93.2]
Vaccine response defined as: post-vaccination rSBA titer C1:32 in initially seronegative subjects; four-fold increase in initially seropositive
subjects with rSBA titer 1:8 and \1:128; two-fold increase in initially seropositive subjects with rSBA titer C1:128
ATP according-to-protocol, N number of subjects with both pre- and post-vaccination results available, n/% number/percentage of responders;
95 % CI 95 % confidence interval, rSBA rabbit complement source
* Statistically significant difference between the MenACWY-TT and MenPS groups (exploratory analysis)
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rSBA GMTs were between 1.9- and 4-fold higher in subjects
who responded to TT: That is, the point values of the rSBA
GMT for each serogroup was higher (no statistical test per-
formed because of the low number of subjects) in subjects
with post-vaccination anti-TT concentrations C1.0 IU/ml
(3,581.8 [95 % CI 2,211.4; 5,801.4] for serogroup A, 3,891.4
[1,605.7; 9,430.6] for serogroup C, 3,750.9 [1,985.8; 7,084.8]
for serogroup W-135 and 7,600.5 [4,588.7; 12,589.3] for se-
rogroup Y) and was lower in subjects in whom the anti-TT
concentration remained \0.1 IU/ml after vaccination
(1,147.8 [891.5; 1,477.7] for serogroup A, 2,101.0 [1,510.1;
2,923.0] for serogroup C, 1,045.1 [788.0; 1,385.9] for sero-
group W-135 and 1,831.1 [1,441.2; 2,326.6] for serogroup Y)
(Supplementary table 3).
3.5 Reactogenicity and Safety
Incidences of local and general solicited symptoms were
very low in both groups. In the MenACWY-TT group pain
was reported by six subjects (2.3 % [95 % CI 0.8; 4.9]) and
redness and swelling each by three subjects (1.1 % [0.2;
3.3]). No local symptoms were reported by subjects in the
MenPS group. No local symptoms of grade 3 intensity
were reported in either group.
Fatigue was reported by five subjects in the MenAC-
WY-TT group (1.9 % [95 % CI 0.6; 4.3]) and no subjects
in the MenPS group. Headache was reported by eight
subjects (3.0 % [1.3; 5.9]) in the MenACWY-TT group
and by two subjects (2.2 % [0.3; 7.9]) in the MenPS group.
Table 3 Percentage of subjects with rSBA titers C1:8 and C1:128 and GMTs (ATP cohort for immunogenicity)
Serogroup Group Time point N C1:8 C1:128 GMT [95 % CI]
n % [95 % CI] n % [95 % CI]
A MenACWY-TT Pre 181 136 75.1 [68.2; 81.3] 104 57.5 [49.9; 64.8] 108.3 [77.9; 150.5]
Post 186 185 99.5 [97.0;100] 177 95.2 [91.0; 97.8] 1,442.3* [1,174.4; 1,771.3]
MenPS Pre 61 43 70.5 [57.4; 81.5] 37 60.7 [47.3; 72.9] 102.1 [55.2; 188.7]
Post 65 65 100 [94.5; 100] 63 96.9 [89.3; 99.6] 2,840.1 [2,062.3; 3,911.1]
C MenACWY-TT Pre 190 135 71.1 [64.0; 77.4] 86 45.3 [38.0; 52.6] 71.5 [51.1; 100.1]
Post 192 192 100 [98.1; 100] 179 93.2 [88.7; 96.3] 2,498.6* [1,887.0; 3,308.2]
MenPS Pre 66 44 66.7 [54.0; 77.8] 29 43.9 [31.7; 56.7] 73.8 [38.0; 143.6]
Post 66 65 98.5 [91.8; 100] 62 93.9 [85.2; 98.3] 4,815.1 [2,827.0; 8,201.2]
W-135 MenACWY-TT Pre 188 135 71.8 [64.8; 78.1] 98 52.1 [44.7; 59.5] 84.7 [61.1; 117.3]
Post 193 188 97.4 [94.1; 99.2] 183 94.8 [90.7; 97.5] 1,454.0 [1,130.5; 1,870.1]
MenPS Pre 62 40 64.5 [51.3; 76.3] 30 48.4 [35.5; 61.4] 68.5 [37.4; 125.3]
Post 66 63 95.5 [87.3; 99.1] 62 93.9 [85.2; 98.3] 1,838.4 [1,134.6; 2,978.9]
Y MenACWY-TT Pre 189 148 78.3 [71.7; 84.0] 118 62.4 [55.1; 69.4] 137.6 [100.7; 187.9]
Post 193 193 100 [98.1; 100] 187 96.9 [93.4; 98.9] 2,547.0 [2,059.6; 3,149.8]
MenPS Pre 64 55 85.9 [75.0; 93.4] 46 71.9 [59.2; 82.4] 217.4 [131.7; 358.9]
Post 66 66 100 [94.6; 100] 65 98.5 [91.8; 100] 3,931.6 [2,726.1; 5,670.2]
ATP according-to-protocol, GMT geometric mean antibody titer calculated on all subjects, N number of subjects with available results, n/%
number/percentage of subjects with titer within the specified range, 95 % CI 95 % confidence interval, Pre Pre-vaccination, Post 1 month post-
vaccination, rSBA rabbit complement source
* Statistically significant difference between the MenACWY-TT and MenPS groups (exploratory analysis)
Table 4 Percentage of subjects with anti-TT concentrations C0.1 and 1 IU/ml and GMCs (ATP cohort or immunogenicity)
Group Timing N C0.1 lU/ml C1 lU/ml GMC [95 % CI]
n % [95 % CI] n % [95 % CI]
MenACWY-TT Pre 192 12 6.3 [3.3; 10.7] 3 1.6 [0.3; 4.5] 0.058 [0.053; 0.063]
Post 192 54 28.1 [21.9; 35.1] 29 15.1 [10.4; 21.0] 0.137 [0.104; 0.180]
MenPS Pre 66 6 9.1 [3.4; 18.7] 1 1.5 [0.0; 8.2] 0.060 [0.051; 0.070]
Post 66 6 9.1 [3.4; 18.7] 1 1.5 [0.0; 8.2] 0.060 [0.051; 0.071]
ATP according-to-protocol, GMC geometric mean antibody concentration calculated on all subjects, N number of subjects with available results,
n/% number/percentage of subjects with concentration within the specified range, 95 % CI 95 % confidence interval, Pre Pre-vaccination, Post
1 month post-vaccination, TT tetanus toxoid
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Fever (defined as axilliary temperature C37.5C) was
reported by six subjects (2.3 % [0.8; 4.9]) in the MenAC-
WY-TT group and by one subject (1.1 % [0.0; 6.1]) in the
MenPS group. All fever episodes were B38.0C except
one, which was [38.0C and one [38.5C in the Men-
ACWT-TT group. No subject in either group reported
gastrointestinal symptoms during the solicited follow-up
period.
No grade 3 local or general symptoms were reported by
either group, and no solicited symptom led to a medically-
attended visit. On observing the low incidences of adverse
reactions after vaccination, the investigator re-questioned
the subjects before the database was unblinded and the
statistical analysis performed, and additional adverse
events were not identified.
One serious adverse event was reported during the study
(reported above). No cases of new onset of chronic disease
were reported during the 31-day follow-up period.
4 Discussion
This is the first study to evaluate quadrivalent MenACWY-
TT in an elderly population. MenACWY-TT was immu-
nogenic in this age group, with at least 93.2 % of vaccinees
achieving rSBA titers C1:128 after vaccination, at least a
13.3-fold increase in post-vaccination rSBA GMTs, and a
VR observed in at least 76.6 % of subjects.
In contrast with previous studies conducted in children,
adolescents and adults, we observed lower responses in the
MenACWY-TT group compared to the MenPS group in
terms of VR (serogroup A) and GMTs (serogroups A and
C), mainly because of a lower response in subjects with high
pre-existing rSBA titers (C1:128), indicative of previous
vaccination or exposure, who received MenACWY-TT.
Immune hyporesponsiveness, in which the individual fails
to mount an immune response after booster vaccination of
at least the same, or of a greater magnitude, than that
achieved after primary vaccination [16], has been well
described in all age groups following repeated vaccination
with serogroup C polysaccharide vaccine [17, 35]. Avail-
able data from studies in adolescents and young adults using
MenACWY-TT or MenACWY-DT (diphtheria toxoid)
show attenuated responses to all serogroups in subjects
previously vaccinated with polysaccharide vaccines com-
pared to vaccine-naı¨ve subjects receiving their first conju-
gate vaccine dose [36–38]. This suggests that conjugate
meningococcal vaccines only partially reverse immune
hyporesponsiveness induced by prior meningococcal poly-
saccharide vaccination. Nevertheless, immune responses
following meningococcal conjugate vaccination in previ-
ously vaccinated subjects were consistently high, with se-
roprotective rSBA levels achieved in the majority of
subjects [36–38]. We observed comparable responses
regardless of previous meningococcal vaccination in the
MenACWY-TT group, except for the lower point values for
serogroup W-135 rSBA titers. This study was not designed
to evaluate booster responses in previously primed indi-
viduals, and we are unable to reach conclusions on the
nature of the responses observed. Further studies are needed
to define how meningococcal polysaccharide vaccination
influences subsequent conjugate vaccination in adults.
Our study is one of the few that provide information on
the immunogenicity of meningococcal conjugate vaccina-
tion in the elderly. ACWY-CRM197 was observed to be
immunogenic in older individuals in a study that included a
cohort of previously unvaccinated subjects between 55 and
65 years of age with SBA titers (human complement
source) that were higher following conjugate vaccination
than after meningococcal polysaccharide vaccination [20].
MenACWY-TT was also immunogenic in all four vaccine
serogroups in subjects whose age ranged between 56 and
103 years. Our study comprised more females than males,
which is typical of the gender distribution of this age group
[39].
Conjugate vaccines using TT as carrier are typically
highly immunogenic, in part related to T-cell help induced
by the TT carrier [40]. We observed a very low percentage
of subjects with anti-TT concentrations C0.1 IU/ml prior to
vaccination and low anti-TT responses to a single dose of
MenACWY-TT, consistent with vaccination practices in
Lebanon where no tetanus booster is routinely recom-
mended after childhood. Similarly low anti-TT seropro-
tection rates have been reported in other countries: In
Turkey, only 15.4 % of nursing home residents (mean age
71 years) had anti-TT antibodies C0.1 IU/ml by ELISA
[41]; in Egypt only 9.7 % of elderly individuals had anti-TT
antibodies C0.15 IU/ml by ELISA [42], while in Spain,
only 7.7 % of individuals over 70 years of age had pro-
tective titers by hemagglutination [43]. This is in contrast to
studies done with MenACWY-TT in other adult popula-
tions where pre-vaccination anti-TT concentrations were
higher (e.g., 51.5 % with anti-TT C0.1 IU/ml prior to
vaccination in an Asian adult population aged 18–55 years,
including adults from Lebanon [21]). The TT component of
MenACWY-TT was highly immunogenic in that study
(percentage of participants with anti-TT C0.1 IU/ml
increased to 79.4 %) [21, 30]. Although vaccination records
were not available, the low responses observed in our study
may reflect a primary immune response, as observed fol-
lowing a single dose of TT in adults with an unknown or
distant history of TT vaccination [44]. The absence of pre-
existing immunity to TT or a vaccine response to the TT
component of MenACWY-TT may have reduced the
available T-cell help, resulting in lower rSBA responses
than previously observed, appearing to particularly affect
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serogroups A and C. This is supported by the observation
that rSBA responses were 1.9- to 4-fold higher in individ-
uals who mounted a booster response to TT (concentrations
C1.0 IU/ml after vaccination) compared with those in
whom the magnitude of the post-vaccination anti-TT con-
centration was lower. Immunogenicity of conjugate vac-
cines using DT and CRM197 carrier proteins is known to
need prior DT priming to generate optimal responses [40].
Our results support the immunogenicity of MenACWY-TT
in TT-unprimed individuals, but suggest that effective TT-
priming may be critical to enhance the immune response to
subsequent TT conjugate vaccines.
Studies of meningococcal conjugate vaccines specifi-
cally evaluating the effects of carrier priming and of prior
polysaccharide exposure on subsequent responses to con-
jugate vaccination are not available. It is not clear whether
the results of our study are predictive for individuals living
in other countries where TT boosters may be more fre-
quently administered and where fewer subjects may have
received prior meningococcal polysaccharide vaccine. It is
possible that in these settings higher immune responses to
MenACWY-TT would be achieved in older adults. How-
ever, this needs to be confirmed in studies conducted out-
side of the Middle East. Antibody persistence and the
response to subsequent MenACWY-TT doses in the elderly
warrant further investigation. It would also be informative
to study the immunogenicity of TT boosters in older
Lebanese adults given the relatively poor response to the
TT component of MenACWY-TT observed in this study.
Both of the meningococcal vaccines were associated
with very low rates of local and general symptoms. This is
consistent with other studies conducted in older individuals
where substantially lower reactogenicity has been reported
compared to administration of the same vaccines to
younger age groups [45].
This study was potentially limited by its open design and
because numerous exploratory statistical comparisons were
performed without adjustment for multiplicity. Therefore,
statistical findings should be interpreted with caution.
Inclusion of adults who had previously received menin-
gococcal vaccine was another potential limitation, although
we performed sub-analyses to attempt to account for any
effects of prior vaccination on the immune response.
5 Conclusion
This study provides the first information on MenACWY-TT
immunogenicity and safety in the elderly. In adults 56 years
of age and older with a varied meningococcal immunization
history, MenACWY-TT was immunogenic, with 93 % of
subjects achieving rSBA titers well above the seroprotec-
tive threshold (C1:128) against all four serogroups after a
single dose. MenACWY-TT was associated with few minor
adverse events.
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